ARAV - Aravive Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-5.683M

Cash

18.36M

Avg Qtr Burn

-17.14M

Short % of Float

20.44%

Insider Ownership

47.53%

Institutional Own.

30.53%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Batiraxcept (AVB-500) Details Renal cell carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batiraxcept (AVB-500) Details Solid tumor/s, Cancer, Renal cell carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batiraxcept (AVB-500) Details Pancreatic cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Batiraxcept (AVB-500) Details Ovarian cancer, Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.